27590 Federal Register / Vol. 63, No. 96 /Tuesday, May 19, 1998 / Notices

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 20,

1998.

Dated: May 6, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13325 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances,

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 27, 1998, Roberts

Laboratories, Inc., 4 Industrial Way

West, Eatontown, New Jersey 07724–

2274, made application by renewal to

the Drug Enforcement Administration to

be registered as an importer of propiram

(9649), a basic class of controlled

substance listed in Schedule I.

The firm plans to import the propiram

to manufacture in bulk for product

development.

Any manufacturer holding, or

applying for, registration as a bulk

manufactuter of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than (30 days

from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 6, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13320 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 23, 1998, Roche

Diagnostic Systems, Inc., 1080 U.S.

Highway 202, Somerville, New Jersey

08876–3771, made application by

renewal to the Drug Enforcement

Administration to be registered as an

importer of tetrahydrocannabinols

(7370), a basic class of controlled

substance listed in Schedule I.

The tetrahydrocannabinols will be

utilized exclusively for non-human

consumption in drug of abuse detection

kits.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than June 18, 1998.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 7, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13333 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on February 17, 1998,

Roche Diagnostic Systems Inc., 1080

U.S. Highway 202, Somerville, New

Jersey 08876–3771, made application by

renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ...... I

Phencyclidine (7471) .................... II

Benzoylecgonine (9180) ............... II

Methadone (9250) ........................ II

Morphine (9300) ........................... II